Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 18/20 | 0.62 |
| ▸ | RARA | P10276 | 17/20 | 0.62 |
| ▸ | RARB | P10826 | 17/20 | 0.62 |
| ▸ | RXRA | P19793 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758473 | 1.00 | RARG (0.62) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL5888210 | 0.93 | RARG (0.60) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL7753760 | 0.93 | RARG (0.60) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL5888058 | 0.91 | RARG (0.50) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL5889205 | 0.90 | RARG (0.63) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL7756362 | 0.90 | RARG (0.56) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL5888192 | 0.90 | RARG (0.56) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL7759665 | 0.90 | RARG (0.49) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL7759663 | 0.90 | RARG (0.49) | RARGRARARARBRXRAKDM4E | |
| SCHEMBL5887941 | 0.89 | RARG (0.60) | RARGRARARARBRXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992095-B2 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | claimed |
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-04-08 | — | — | US | claimed |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | BERNARDON JEAN-MICHEL (FR) | 2002-01-24 | — | — | US | claimed |
| US-6214878-B1 | SKIN DISORDERS; RHEUMATIC DISEASES; RESPIRATORY SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2001-04-10 | — | — | US | claimed |
| EP-0850909-B1 | Stilbene compounds with adamantyl group, compositions containing the same and uses | CT INTERNAT DE (FR) | 2001-03-21 | — | — | EP | claimed |
| EP-0850909-A1 | Stilbene compounds with adamantyl group, compositions containing the same and uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-07-01 | — | — | EP | claimed |
| US-6992095-B2 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-04-08 | — | — | US | disclosed |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | BERNARDON JEAN-MICHEL (FR) | 2002-01-24 | — | — | US | disclosed |
| US-6214878-B1 | SKIN DISORDERS; RHEUMATIC DISEASES; RESPIRATORY SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2001-04-10 | — | — | US | disclosed |
| EP-0850909-B1 | Stilbene compounds with adamantyl group, compositions containing the same and uses | CT INTERNAT DE (FR) | 2001-03-21 | — | — | EP | disclosed |
| EP-0850909-A1 | Stilbene compounds with adamantyl group, compositions containing the same and uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RARG 1564/4885RARA 1151/4885RARB 406/4885 |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RARG 1564/4885RARA 1151/4885RARB 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.